Combined Biparametric Prostate MRI and Prostate Specific Antigen in the Detection of Prostate Cancer: a Validation Study in a Biopsy Naïve Patient Population.

To validate the use of biparametric (T2- and diffusion weighted) magnetic resonance imaging (B-MRI) and prostate-specific antigen (PSA)/PSA density (PSAD) in a biopsy naïve cohort at risk for prostate cancer (PCa).

All patients (n=59) underwent PSA screening and digital rectal exam (DRE) prior to a B-MRI followed by MRI/transrectal ultrasound (TRUS) fusion-guided targeted biopsy. Previously reported composite formulas incorporating screen positive lesions (SPL) on B-MRI and PSA or PSAD were developed to maximize PCa detection. For PSA, a patient was considered screen positive if PSA level + 6 x (the number of SPL) >14. For PSAD, screening was positive if PSAD x 14 + (the number of SPL) >4. 25. These were employed in this new test set to validate the initial formulae. Performance assessment of these formulas was determined for all cancer detection and for tumors with Gleason ≥3+4.

SPL on B-MRI had the highest sensitivity (95. 5%) and negative predictive value (NPV) of 71. 4% compared to PSA and PSAD. B-MRI significantly improved sensitivity (43. 2 to 72. 7%, p=0. 0002) when combined with PSAD. The NPV of PSA increased with B-MRI, achieving 91. 7% for B-MRI and PSA for Gleason ≥3+4. Overall accuracy of the composite equations was 81. 4% (B-MRI and PSA) and 78. 0% (B-MRI and PSAD).

Validation with a biopsy naïve cohort demonstrates the parameter SPL performed better than PSA or PSAD alone in accurately detecting PCa. The combined use of B-MRI, PSA, and PSAD resulted in improved accuracy for detecting clinically significant PCa.

Urology. 2015 Dec 08 [Epub ahead of print]

Michele Fascelli, Soroush Rais-Bahrami, Sandeep Sankineni, Anna M Brown, Arvin K George, Richard Ho, Thomas Frye, Amichai Kilchevsky, Raju Chelluri, Steven Abboud, M Minhaj Siddiqui, Maria J Merino, Bradford J Wood, Peter L Choyke, Peter A Pinto, Baris Turkbey

National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland; Departments of Urology and Radiology, University of Alabama at Birmingham. , National Cancer Institute, National Institutes of Health, Molecular Imaging Program, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Molecular Imaging Program, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland; Department of Surgery, Division of Urology, University of Maryland, Baltimore. , National Cancer Institute, National Institutes of Health, Laboratory of Pathology, Bethesda, Maryland. , Department of Radiology and Imaging Services, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Center for Interventional Oncology, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Molecular Imaging Program, Bethesda, Maryland. , Department of Radiology and Imaging Services, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Center for Interventional Oncology, Bethesda, Maryland; National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, Maryland. , National Cancer Institute, National Institutes of Health, Molecular Imaging Program, Bethesda, Maryland.  

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe